SPP Forecasting and Demand Planning and Supply Chain Mapping seeking to deliver a paradigm change

SPP Forecasting and Demand Planning and Supply Chain Mapping seeking to deliver a paradigm change

  • Home
  • News and Papers
  • SPP Forecasting and Demand Planning and Supply Chain Mapping seeking to deliver a paradigm change

Launched in response to a request by biopharmaceutical manufacturers and suppliers, the Supply Partner Phorum (SPP) is designed to bring together both parties to work together to tackle and solve issues with the inbound supply chain; an area of vital importance throughout the Biopharmaceutical Industry.

The SPP provides a trusted environment for both parties and it is easy to see why manufacturers benefit from working with the suppliers: it leads to a better understanding of the whole supply chain and the source of their raw materials; it creates a better way of working together to meet the challenges of material  demand and supply and is an area where improvements and increasing collaboration can benefit both individual companies and the industry as a whole as we seek to meet the capacity and capability challenges  of the future.

 

Marin Henley, Manager Capital Equipment Sourcing at Bristol Myers-Squibb, summarises the role of the SPP: “This phorum represents the ability of biopharma manufacturers to interact with our suppliers and to do so on a pretty even playing field meaning that there is no inhibition in terms of communicating back and forth as we share the same goal of making the industry better”.  

The SPP is developing and, as it matures, is starting to address areas of non value added waste seeking to reduce, or potentially eliminate these, to improve efficiency and quality. It is also beginning to look at the scope for the SPP to act as a catalyst for change and a source of education across the Industry in areas of mutual interest between drug manufacturers and supply partners.

After its first successful year in operation, the phorum has commissioned  two distinct, yet related, SPP workstreams: Forecasting and Demand Planning and Supply Chain Mapping. Each workstream has, currently, some 20 different companies engaged with representatives of both biomanufacturers and supply partners sharing their knowledge and experience. Henley summarises the goal of the phorum’s two workstreams:“We’re working right now on creating position papers for the industry on both supply chain forecasting and supply chain mapping where we can leverage best practices and highlight issues that both biopharma manufacturers and our supply base experience and understand where there are opportunities for improvement”.

Forecasting and demand planning (FDP)

This workstream was established to address some of the critical issues  that can arise through a lack, or potential lack, of supply of critical products to manufacturers; an area of particular concern as global capacity demands increase.  Establishing a ‘common language’ and sharing openly the processes and underpinning assumptions are  key elements in the progress already seen with this workstream. The recent face to face meeting in April 2017 demonstrated the value of simply increasing understanding between drug manufacturers and supply partners by discussing, and challenging, the processes and the actions taken by subject matter experts..

Forecasting and demand planning operates at 2 levels. Firstly,  at the individual company interaction with their supply partner. Secondly, in areas of demand that could, potentially,  be consolidated across the  industry with a critical question to consider: if  there is enough capacity in the industry to support the provision of critical raw materials to meet anticipated demand growth?   The supply chain must be capable of dealing with the demands that the industry makes of it and if, as industry experts predict,  there is going to be  significantly more demand generated for raw materials and services in key areas of the inbound supply chain as overall capacity demands increase, will existing systems and processes be sufficiently agile and robust to meet the challenges ahead?  At the recent Face to Face, the workstream started to map out a “high level” model of a possible future forecasting and demand planning process. The aim is to now refine and build on this model with the intention of publishing a best practice guide in this important area for use across the Industry toward the end of 2017. While implementation and adoption will undoubtedly provide a challenge to be overcome, the sense is that this workstream can act as a catalyst for an increasingly standardised approach in the Industry as we develop and adapt our supply chain processes to meet the capacity challenges of the next few years.

Supply Chain Mapping (SCM)

There are increasing pressures on the Industry to gain greater transparency and visibility throughout the supply chain from original raw material source through to the final product and including the  various “touch points” involved throughout.  The Supply Chain Mapping workstream was commissioned by the SPP as a response to this Industry wide need and seeks to understand the current state of the Industry and to then design a ‘model for good’ that can be incorporated into a best practice guide for supply chain mapping in biopharma.   It has, so far, proved both a fascinating, if challenging, journey to seek to understand the different levels of maturity of supply chain mapping across the Industry and to begin to identify areas where, perhaps, we might seek to align interests and processes as the Industry further matures. The workstream has some 20 companies represented with a great mix of experience and expertise representing drug manufacturers and supply partners.

There are many reasons for examining and then accurately mapping the supply chain  ranging from ensuring continuity and security of supply to compliance with legislation from the FDA or its European counterparts and to ensurance of patient safety.  These issues extend beyond the source of raw materials to how they are stored and transported and effective supply chain mapping must therefore embrace the totality of the supply chain; a complex and challenging task which the SCM workstream is currently about half way through in the program to deliver a best practice guide. .

In the longer term both SPP workstreams  are looking at solutions that the industry could implement and the scale of adoption and implementation will, in part, be a measure of the success of the work being undertaken.

The Supply Partner Phorum is a developing phorum with membership still open to those biomanufacturers and suppliers who want take part in the collaboration.

Contact address

BioPhorum
The Gridiron Building
One Pancras Square
London
N1C 4AG

Newsletter subscribe

You can unsubscribe at any time by clicking the link in the footer of our emails. For information about our privacy practices, please visit our website.



© 2019 Biophorum Operations Group · All Rights Reserved

Registered Address: 5 Westbrook Court · 2 Sharrow Vale Road · Sheffield · S11 8YZ

Company Number 06794795 · VAT Number GB298617544

Driving progress in Cell & Gene Therapy

Now with 19 member companies and 183 subject matter experts, the BioPhorum Cell & Gene Therapy (C>) Phorum has made great strides since its formation[...]

Read More
Cell and Gene Therapy Phorum accelerates progress

The BioPhorum Cell & Gene Therapy Phorum has made significant progress since its creation in 2018 – from building networks and sharing knowledge to endorsing[...]

Read More
2018 highlights

BioPhorum’s mission has always been to make the journey for tackling industry challenges better, faster and cheaper for members. By helping you to work on[...]

Read More
Industry bioassay approach helps to shape the future

In 2018, members of the Development Group Bioassay workstream came together to write a best practices paper on bioassay development. We are delighted to announce[...]

Read More
Sharing ideas on forced degradation

“Forced degradation studies are an important part of the drug lifecycle process as they can inform many aspects of drug development,” said Jennifer Halley, Principal[...]

Read More
The BioPhorum and USP collaborative journey to new standards

BioPhorum and United States Pharmacopeia (USP) share a common direction – to accelerate biopharma innovation, quality and progress through collaboration.

Read More
Proactive prioritization: a new tool for assessing raw material risk

The Raw Material Risk Management workstream has launched a new, raw material risk assessment tool aimed at helping industry identify and prioritize around the challenging[...]

Read More
How well can you handle SUS changes?  Take our surveys and see

BioPhorum delivery of value from the disposables five-year plan - supplier change notifications for single-use systems

Read More
2018 highlights

BioPhorum’s mission has always been to make the journey for tackling industry challenges better, faster and cheaper for members. By helping you to work on[...]

Read More
Hi-tech ambitions for Fill Finish

The Fill Finish Phorum has recently embarked on a series of exciting and ambitious initiatives, exploring new technologies and processes to enhance the efficiency and[...]

Read More
Companies poised to follow ARMM recommendations

The Advanced and Rapid Microbial Methods (ARMM) team set out a clear case for modernizing Environmental Monitoring (EM) in grade A settings: in summary bio-fluorescent[...]

Read More
How to achieve the ‘Goldilocks’ amount of environmental monitoring

Regulators require a risk-based approach to environmental monitoring (EM)… but they give no clear definition of what “risk-based” actually means. The aim of the Environmental[...]

Read More
Logistics collaboration hub: An opportunity for significant time and cost savings

Most biopharmaceutical manufacturers use a network of logistics service providers (LSPs) to deliver warehousing, transport and distribution services, and they are usually linked using customized,[...]

Read More
The ‘how to’ guide to implementing Agile in GxP

The publication of the Guidance on the use of Agile in a GxP Environment document in 2017 was well received.It described how the use of[...]

Read More
How smart is your maintenance?

Faster. Cheaper. Smarter. All companies are under pressure to achieve more with less, not least with their maintenance programs. But while ‘faster’ and ‘cheaper’ maintenance[...]

Read More
Supply chain, forecasting and demand planning solutions gain momentum

The relationship between suppliers and manufacturers is one of the most crucial in biopharmaceutical manufacturing. This is especially the case when forecasting and supply planning.[...]

Read More
2018 highlights

BioPhorum’s mission has always been to make the journey for tackling industry challenges better, faster and cheaper for members. By helping you to work on[...]

Read More
BioPhorum and Rx-360 pilot a joint audit model for single-use systems

BioPhorum and Rx-360 have agreed a pilot to validate the use of the Joint Audit Model in the single-use systems supply chain.

Read More
Removing the roadblocks to continuous biomanufacturing

Continuous downstream processing is increasingly seen as a feasible approach for manufacturing biologics. The industry recognises that it offers advantages over batch-based processing by:

Read More
Changing mindsets with a modular approach

Historically, manufacturers have used a ‘waterfall’ approach when designing and building their production facilities, sequentially resolving and specifying all aspects up front and in detail[...]

Read More
How do you bring technology roadmapping to life?

You use it to make change happen and that is exactly what the Phorum’s leaders did after the first edition of the Biomanufacturing Technology Roadmaps[...]

Read More
Slicing years off change implementation

As the first regulatory authority in Latin America to gain full membership of the International Council for Harmonization (ICH), the Brazilian Health Regulatory Agency (Anvisa)[...]

Read More
BioPhorum Regulatory Interaction: helping to open doors

To implement any change in the biopharmaceutical manufacturing industry it is important to engage with and collaborate with the regulators. Set up two years ago,[...]

Read More
Regulatory compliance: what lessons can be learned?

BioPhorum delivery of value from the disposables five-year plan - supplier change notifications for single-use systems

Read More
Navigating the maze of medical technology regulation: a solo voyage or a team effort?

Medical technology is a global business, generating annual revenues of over $400bn. The sector encompasses a broad range of technologies: from in-vitro diagnostics and diagnostic[...]

Read More

IaaS Cloud webinar recording play back
Read More
New BPIT guidance to align cloud services to regulatory requirements
Read More
Data Integrity and Agile Webinars to support industry response to regulators
Read More
How to validate informatics in CPV programs

The BioPhorum Continued Process Verification (CPV) and Informatics team has published a paper to support a risk-based approach for the validation of informatics systems for[...]

Read More
Continued Process Verification delivering real saving in time and money

More than 50 per cent of biopharma products on the market now have Continued Process Verification (CPV) plans in place.  Thanks to the CPV white[...]

Read More
A roadmap for the implementation of continued process verification

This article provides a roadmap draws on the content of the CPV case study to provide a step-by-step guide in a more accessible form.

Read More
How smart is your maintenance?

Faster. Cheaper. Smarter. All companies are under pressure to achieve more with less, not least with their maintenance programs. But while ‘faster’ and ‘cheaper’ maintenance[...]

Read More
Digital plant maturity model webinar replay
Read More
Digital Plant Maturity Model workstream to host webinar
Read More
New guidance available on Forecasting and Demand Planning to streamline supply chain performance
Read More
Host cell proteins poster

This poster presented at the BEBPA Conference, San Francisco builds and consolidates the information currently available in the industry for assessing process risk from Host[...]

Read More
Host cell protein risk assessment, an industry approach

Host cell protein (HCP) constitutes a significant class of process-related impurities in biological drugs.

Read More
BEBPA risk assessment workshop
Read More